Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA.
| Revenue (Most Recent Fiscal Year) | $130.13M |
| Net Income (Most Recent Fiscal Year) | $-260.60M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 28.77 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 207.71 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -123.19% |
| Net Margin (Trailing 12 Months) | -123.26% |
| Return on Equity (Trailing 12 Months) | -739.62% |
| Return on Assets (Trailing 12 Months) | -44.27% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.30 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.13 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.89 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.30 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.81 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.34 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.81 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 63.62M |
| Free Float | 59.74M |
| Market Capitalization | $3.94B |
| Average Volume (Last 20 Days) | 0.61M |
| Beta (Past 60 Months) | 2.36 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.10% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |